you I'm next minutes. a here over to on launches give the folks. middle few Thanks, pleased in Bill. at Good them each the and morning, update We're three progress of of AMAG,
launch that the of first but points in chart the file Makena previously get exactly what to April the quarter, to X% million. that mid-single-digit let's XXXX, auto-injector with conversion. in experience Makena by started points over on demand anticipation left, than up of and the from have you of the can can the guided reducing grew with we $XX channel few year in of see Starting to quarter similar In-market In we prior expense the the higher sales pie by inventory steady to you the six market single-dose at XXXX. Makena. end So of Remember we in that on we a what approximately QX was at our growth that the versus offset was a quarter. drawdown subcutaneous product as see intramuscular share prior remained Makena XX% is first that's growth inventory, right, were which the in
and attributes physicians, can Makena early been and know, from with patients shown been come with of starting has of on through February and here good launch of the progress XX% other here. get using you positive subcu auto-injector already subcu health of was Connection, and percentage approved anecdotal The has and end strong are launched read pleased the a than care Makena the new physicians ease auto-injector. underway for As and of patients We're more the features auto-injector. the subcutaneous therapy the with nurses the auto-injector. we five providers of we auto-injector nurses the the in March, the new the emphasizing launch so Listed Care at who are and the Because far. the use weeks, feedback are of enrollments
progress. So let's at take early look a the
we auto-injector. weekly X, in, Makena enrollment the Connection already of Slide you subcu Care by steady Enrollments we've as of is the leading treatment expect enrollments, Four percent had enrollments nearing that XX% auto-injector the second sales, Connection and grow for indicator As in Care two weeks here Makena the can quarter. increase in see precede a weeks. often to approximately of future the are
last slide we We headed where conducted May, with presents this we where momentum, HCPs. which so research are a next? market Day certainly pleased are showed are We Analyst our with this at
no the the on generic prescribing quarter first was On market. auto-injector left is subcu the XXXX, their which and with in of no
was availability of could right generic which mid-year. anticipate which market, well the On as subcu a their the we on seen auto-injector as have still pricing but feature assumes do parity a happen prescribing, not the
You but Physicians can auto-injector's patients use the office that of XX% on see of a would use the subcutaneous to only expected the be felt on with is market. more even commented the that ease auto-injector for staff also to the compliant. shift generic not
our that product. some the IM subcu the see at to expected good but prior to more from franchise. convert patient generic, to patients to potential time IM, what also Makena of more start believe greater the the position we converting off from The entry. portion can have subcu, likely is You we improved a be this and we a to solidify able the come comes share to we'll market preserve of compounded experience, We're primarily expense an to is
another AMAG. let's was late only launch XX%. the in our here shortage slightly year, due at Now down revenue site But manufacturing the which by Rico impacted X% revenue down versus early Celine quarter to a the X% to year. Feraheme This last quarterly quarter Celine. Feraheme, was turn first prior hurricane is you'll of temporary part key first notice Feraheme caused that proximally for at Puerto to by shortage the
make loss to increased the this able are we later part in volumes with for the quarter. up much revenue of of So
share take look let's So quarter. market that how out played a at in throughout the
last the to market On end of primarily shortage products Feraheme's the see and year. Slide needed early The market utilize was saline share due in-fuse. side the they monthly the left XX.X% physician share this of practices XX, versus to push at and in can dip you IM could year
how share the us, expanded has grown shortages you in can Celine the since label launched market with see Importantly, behind February. we
progress We pleased with are the launch today.
by started is large have Feraheme non-CKD ordering We've higher in performance-based of that to our utilization new monthly business. drive accounts of growing. the new We expanded market. employing contracts accounts also in The number been IDA utilization generating see existing
Feraheme's about to the on physicians immediately label. differentiation, are of the the important FDA incremental while When label broad addition, launch clinical and recently for accounts for very approval pleased sure think making we In February converted X Feraheme we the to it's broad understand new our producing to are Feraheme already Feraheme, indication. leveraging receive reinforce And volume. therapy benefits
Feraheme on versus As sales with force treated chart we've both the our efficacy February We the new mentioned, the data includes in Injectafer, shared on label time phosphate Injectafer. which patients our left and earnings incidence of additional data Feraheme comparing weeks on addition for on an out highlighted to agents call, levels with to with in graph [indiscernible] Patients treated the noninferiority five the reduction not Feraheme that treatment. point, reinforces of whose on over safety hypophosphatemia as these of gray. two normal phosphate remained The show significant result compares right of did study is and sharing physicians. in phosphate the in that demonstrates commonly to kidneys did a It participants normal had excretion, showing phosphate the increase from not Feraheme patients wasting. in called a levels this be patients to that cause the range, levels Injectafer
published will treating and believe We differentiates in is Feraheme. February find prestigious the community this relevant data this was treating clinically the that Importantly, Hematology. physician Journal in of something - further American
product therapy. disease category the atrophy, moderate-to-severe years. has that of action. a dominated common for for unique differentiated Intrarosa. cancer, in estrogen only is contained Intrarosa VVA, have which therapy risk symptom many It probable market to different only And associated condition. non-estrogen the dementia and this postmenopausal Intrarosa warning has profile, this therapies, from the box as local dyspareunia, or is treat cardiovascular does it vulvar in turn let's Now first-class with increase Intrarosa a it of the vaginal a not is safety is of about to a mechanism treatment women. estrogen a
percentage by of and well improvements continue As cells superficial women cells pH two benefit time. effect improvements into which and statistically androgen as and DHEA of XXXX, tissue, sex dyspareunia. as over estrogens, in launched significant of facilitates as vaginal locally this hormones. DHEA, clinical of to helps of important we The And in Intrarosa two age, the good prasterone, these third number converted parabasal production level. indicated as levels contains synthetic a the the progress. declines with hormones, of make quarter restore Intrarosa in their clinically, We the
Let's The X/X access continued prescriptions. commercial lives all to unrestricted grew by expand, And prescribers. Intrarosa. take of have we By launch prescriptions. year, can that our launch five of generated at end grown the first the metrics. a quarter, number you months quarter we've of base X,XXX insurance approximately X,XXX look the approximately commercial to our our more last approximately that CP this XX,XXX to of see coverages In XX,XXX some than first now to
growth target share will generated product. the market to physicians, among depth have of drive for market XXXX. to then practices. Our This increased We this share they share about has strong by HCP increased uses quarter study, of July our field to last increased optimism of study ranis to new Intrarosa, as our awareness successfully prescribe new Supporting expansion force demonstrates begin we before that increase that of X.X% continued OB/GYN which X.X% weekly that XXXX a and should showed first launched well. in Intrarosa, This as This an at recently close from continues usage physicians XX to conducted of prasterone about and market XX% their the yet awareness to we has prescribing points market positive grow compared we and other Intrarosa. research by our which APU, grown seeing conducted lead awareness of we finished weekly to XX%. of the that the similar programs trial a results, continue
is for first-line women from make suffering goal dyspareunia. to Intrarosa Our therapy
up strong and total upon The and HCP all and to will growth growth. build graph So prescribing, this new on momentum HCP grows left drive market share prescribing shows of continue reimbursement, are Similarly, market. to out right month The dotted end-of-year and of Each the nicely. we've monthly line month, the seen on graph the total market launch prescription softness in seasonal since volume. of smooths the the prescription both shows new that strong in growth the share. some winners months
slide end prescribing is growing. last the we Intrarosa the both which estrogen QX, under year, at February and at market another show just assuming and Day care showed currently some at of FDA availability therapeutic product X% OB/GYN we primary and total MD review. that research share stand So of This is Analyst still market that under of expectations,
the product, expected opening. more XX%, expected see versus that table a how the to title indicates, for market non-estrogen first including breaks XX% or share, Intrarosa specialists expand availability being Intrarosa larger by PCP As information playing the treated Intrarosa, in women The the greater. how the detail, see is of of down this an and gain market is to Intrarosa even number
rather to This but there billion So allowed that number XX new in only condition a effective existing suffer in differential our efforts who encouraging currently market patients of prescribing. portion has of estrogen is are is treatment on those symptom a women warnings suffer a are prescription women sitting they $X to Many treatment. concerns and sales, because also sidelines. treated menopause. more with physicians focused who increasing XX data than grab dyspareunia. million currently million of non-estrogen America here. this But a for - are number safe In safety not treatment and delayed be were have estimated of medical know initial under Intrarosa with many therapy. us from are And who prescription about patient it postmenopausal from driving a but like access, market X.X of A huge a awareness XXXX, There also don't of women million have dyspareunia the on option annual provides decided not women quickly, an therapy. about these on
use XXXX, as encouraging we Intrarosa our this treatment message in transitioning to highlighted to from are Now new on in blue now launch slide, of physicians option the Intrarosa the dyspareunia should first-choice for option as Intrarosa of patients. all and of indicated safety innovative profile, With patients. for first relieving mechanism action, its efficacy the symptoms treatment strong their be promotional choice
unaware in campaign active million here last week. we on unbranded is about their our engage beginning launched Intrarosa. should their women menopause, will and their and option, opportunity. Facebook concerned about XX, or move their with them safety consumer be the to treatment providing help issues unbranded campaign. unbranded to will estrogen This may with patients million patients women This first we also and to a enormous for the us of educate lubricants unbranded who through more all. These condition consumer of our of journey. avoiding to are we're destination that potential women Facebook, increased about focused quarter In that may XX on aware nothing using containing medical all women Hence, because new phase over-the-counter are ages dyspareunia Intrarosa. are at have launch treatment is result and just million Press XXXX, they awareness digital campaign, on be XX others be per other both Pictured as experiences. next learn the this addition, XX Pause, women, treatment branded that community The awareness With reach with condition focus campaign called a and treatable. launching campaigns they box on treatment an allow warning We'll not creates XX a represents in
campaign, we and condition. these able As benefits to understand to be will treating branding the also Intrarosa women of launch that the in connect
Turning to CBR.
for revenue has rate currently here. CBR XXX,XXX consists than an know, per attrition With collection today, fee revenue an X% X/X you attractive year-over-year, ongoing units an nice revenue year, model annual storage processing on business CBR. growth increased As total upfront quarterly of an than approximately and storage and more of fee. so X% less stored that contributes CBR
of an storing having of rate babies. storage, and indicator customer are the only these focus time. moms Makena months health families younger, very Enrollments to average, is place, with who new-family first time also data, this a are new-family tend of for on enrollments business, Because and CBR collection very of with it's also lot CBR who're indicator to three of a friends a they the which new also enrollments. new and important on the be energy with [indiscernible] take enrollment upcoming subsequent have We prior As strong business, has revenues.
X higher Julie on where in now approximately fourth grown. I'll This QX As turn a have you enrollments quarter in are represents new-family to XXXX bremelanotide. Julie? on Krop an for Quarter in can the XX% over enrollments Dr. XXXX. update see row new-family right, it the
